NO20052009L - Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom - Google Patents

Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Info

Publication number
NO20052009L
NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
Authority
NO
Norway
Prior art keywords
treatment
myelodysplastic syndrome
acute leukemia
combination therapy
pharmaceutical combinations
Prior art date
Application number
NO20052009A
Other languages
English (en)
Other versions
NO20052009D0 (no
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20052009D0 publication Critical patent/NO20052009D0/no
Publication of NO20052009L publication Critical patent/NO20052009L/no

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives fremgangsmåter for behandling og farmasøytiske kombinasjoner for behandlingen av akutt leukemi, så som akutt myelogen leukemi og myelodysplastisk syndrom. Fremgangsmåtene og de farmasøytiske kombinasjonene benytter et anti-CD33 cytotoksisk konjugat i kombinasjon med minst én forbindelse valgt fra gruppen bestående av et antracyklin og en pyrimidin- eller purin-nukleosidanalog. Foretrukne fremgangsmåter for behandling og farmasøytiske kombinasjoner benytter gemtuzumab ozogamicin, daunorubicin og cytarabin.
NO20052009A 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom NO20052009L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
NO20052009D0 NO20052009D0 (no) 2005-04-25
NO20052009L true NO20052009L (no) 2005-06-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052009A NO20052009L (no) 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Country Status (10)

Country Link
EP (1) EP1575582A4 (no)
JP (1) JP2006508119A (no)
CN (1) CN1720044A (no)
AU (2) AU2002348178A1 (no)
BR (1) BR0215935A (no)
CA (1) CA2504611A1 (no)
CR (1) CR7804A (no)
MX (1) MXPA05004711A (no)
NO (1) NO20052009L (no)
WO (1) WO2004043461A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
KR20080030659A (ko) * 2005-07-06 2008-04-04 카니사 파마슈티컬즈, 인크. 칼리키아미신-항체 컨쥬게이트를 조스퀴다르와 조합하여사용하는 암 환자의 치료
ATE521366T1 (de) * 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
EP2084527A4 (en) * 2006-11-02 2011-07-27 Seattle Genetics Inc METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
DK2120568T3 (en) * 2007-02-16 2017-12-11 Celator Pharmaceuticals Inc FIXED PHARMACEUTICAL CONDITIONS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS
EP2649997B1 (en) 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
EP2333108A4 (en) 2008-08-29 2012-05-09 School Juridical Person The Kitasato Inst METHOD FOR DETERMINING THE HEALING EFFECT OF DNA METHYLATION INHIBITORS
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (en) 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS
IL271475B2 (en) * 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
BR112021014625A2 (pt) * 2019-01-28 2021-10-05 Board Of Regents, The University Of Texas System Método para tratar uma doença em um sujeito mamífero, método para reduzir ou eliminar uma ou mais mutações ou anormalidades citogenéticas nas células cancerosas de um sujeito com câncer, método para diagnosticar um sujeito com uma doença proliferativa responsiva à terapia de quelação, método para diagnosticar e tratar um sujeito com uma doença proliferativa responsiva à terapia de quelação, composição farmacêutica ou combinação farmacêutica, quelante de metal, terapia anticâncer, e antioxidante e/ou mineral
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
US20240000846A1 (en) * 2020-10-27 2024-01-04 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Also Published As

Publication number Publication date
CA2504611A1 (en) 2004-05-27
EP1575582A1 (en) 2005-09-21
NO20052009D0 (no) 2005-04-25
EP1575582A4 (en) 2009-03-11
CN1720044A (zh) 2006-01-11
JP2006508119A (ja) 2006-03-09
CR7804A (es) 2008-10-29
MXPA05004711A (es) 2005-08-03
BR0215935A (pt) 2005-08-09
AU2002348178A1 (en) 2004-06-03
AU2010201113A1 (en) 2010-04-15
WO2004043461A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
NO20052009L (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
WO2022047065A3 (en) Compounds and methods for treatment of viral infections
CY1113012T1 (el) Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
HRP20070383T3 (en) Rapamycin carbohydrate derivatives
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
BRPI0503981A (pt) substituto do açúcar apetecìvel, de baixa caloria com agente de volume insolúvel em água
MXPA05012788A (es) Analogos de nucleosidos fluorados modificados.
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
NO20061402L (no) Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler
WO2004028475A3 (en) Glycosylceramide analogues
ATE274913T1 (de) Wässerige zusammensetzung enthaltend amphotericin b
BRPI0518700A2 (pt) combinaÇÕes antitumorais, contendo um agente inibidor de vegf e 5fu ou um de seus derivados
WO2008104893A3 (en) Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof
HUP0300219A2 (hu) L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
WO2005000204A3 (en) Pancreatic cancer treatment
DK1079840T3 (da) Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer
UA83204C2 (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластичного синдрома
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
HUP0402401A2 (hu) Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
BR0104352A (pt) Taxanos substituìdos por c10 carbamoilóxi como agentes antitumorais
ZA200405345B (en) Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins.
TW202417008A (zh) 1'-氰基核苷類似物及其用途

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application